Regen BioPharma Inc (RGBP)

[Biotechupdates]

Dr Thomas Ichim is on to next venture, CELZ


https://finance.yahoo.com/news/creative-medical-technology-holdings-appoints-110000078.html?.tsrc=applewf


Creative Medical Technology Holdings Appoints Internationally Renowned Stem Cell Pioneer as Chief Scientific Officer

PR Newswire PR NewswireMarch 8, 2017
SAN DIEGO and PHOENIX, March 8, 2017 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (CELZ) announced today the appointment of Dr. Thomas Ichim to the position of Chief Scientific Officer. Dr. Ichim will lead development of the Company's clinical stage CaverStemTM personalized stem cell therapy for erectile dysfunction, as well as advance preclinical and eventually clinical studies on the Company's universal donor AmnioStemTM stem cell therapy for post-stroke recovery.
"It is my honor to welcome Dr. Ichim to the position of Chief Scientific Officer," said Timothy Warbington, President and CEO of CELZ. "I have known Dr. Ichim for more than 10 years and have witnessed him grow his previous company, Medistem Inc., from concept to FDA Investigational New Drug (IND) clearance, to eventual acquisition by the NYSE traded company Intrexon. I am confident that Dr. Ichim will put CELZ on the same trajectory of success."


SAN DIEGO and PHOENIX, March 8, 2017 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (CELZ) announced today the appointment of Dr. Thomas Ichim to the position of Chief Scientific Officer. Dr. Ichim will lead development of the Company's clinical stage CaverStemTM personalized stem cell therapy for erectile dysfunction, as well as advance preclinical and eventually clinical studies on the Company's universal donor AmnioStemTM stem cell therapy for post-stroke recovery.
"It is my honor to welcome Dr. Ichim to the position of Chief Scientific Officer," said Timothy Warbington, President and CEO of CELZ. "I have known Dr. Ichim for more than 10 years and have witnessed him grow his previous company, Medistem Inc., from concept to FDA Investigational New Drug (IND) clearance, to eventual acquisition by the NYSE traded company Intrexon. I am confident that Dr. Ichim will put CELZ on the same trajectory of success."

"Having published 20 peer-reviewed papers with Dr. Ichim over the last nine years, I greatly respect his unique ability to rapidly accelerate progress from concept, to patent, product. I look forward to continuing our collaborations in his new position," said Dr. Amit Patel, Cofounder and Board Member of CELZ, and Head of Cardiac Surgery at University of Miami.

"Dr. Ichim represents a true visionary in the area of cellular therapy, being one of the few people that effectively combines deep knowledge of basic science, regulatory affairs, and clinical translation. I plan to leverage our existing strengths at the Pacific Neurosciences Institute and at St John Providence to accelerate neurological uses of the Company's AmnioStemTM stem cell, particularly in the indication of post-stroke recovery," said Dr. Santosh Kesari, MD, PhD, FANA, FAAN, Scientific Advisory Board Member of CELZ. Dr. Kesari is Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, as well as Director of Neuro-oncology, Providence Saint John's Health Center and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute.